A New Approach to Evaluate Quality Adjusted Life Years using Proxy Utility Function - An Application to HIV/ AIDS Data
Abstract
Estimation of Quality Adjusted Life Years (QALYs) is pivotal towards economic evaluation and cost-effectiveness analysis of medical interventions. Most of the methods developed till date for calculating QALYs are based on multi-state structures where fixed utility values are assigned to each disease state and total QALYs are calculated on the basis of total lengths of stay in each state. In this article, we have presented a new proxy approach to define utility as a function of risk factors, which can be used to calculate QALY without defining discrete disease states. Retrospective survival data of HIV/ AIDS patients undergoing treatment at the Antiretroviral Therapy (ART) center of Ram Manohar Lohia hospital in New Delhi has been used to demonstrate implementation of the proposed methodology. Joint modelling, with a mixed effect longitudinal sub-model for CD4 count and a Cox proportional hazard survival sub-model with time dependent covariates, has been used to estimate risks associated with different factors and covariates. Using the proxy utilities, QALYs have been calculated for each individual for their lifetime time horizon, defined as the time since their registration in the ART till death or till their age reach average life expectancy of HIV/ AIDS patients in India. QALY results are consistent with findings of conventional cost-effectiveness studies on ART for HIV/ AIDS patients in India.
References
Briggs A, Sculpher M. An introduction to markov modelling for economic evaluation. Pharmacoeconomics
; 13(4): 397-409.
Speight PM, Palmer S, Moles DR et al. The costeffectiveness of screening for oral cancer in primary
care. Health Technol Assess 2006; 10(14): 1-144.
Coon JT, Hoyle M, Green C et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal
cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 2010; 14(2): 1-184.
Wu B, Li T, Cai J et al. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with
gastric cancer after D2 gastrectomy. BMC Cancer 2014; 14: 984.
Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in
model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics
; 32(2): 101-108.
Mihaylova B, Briggs A, O’Hagan A et al. Review of statistical methods for analysing healthcare resources
and costs. Health Economics 2011; 20: 897-916.
Malehi AS, Pourmotahari F, Angali KA. Statistical models for the analysis of skewed healthcare cost data: a
simulation study. Health Economics Review 2015; 5-11.
Welton NJ, Ades AE. Estimation of Markov Chain Transition Probabilities and Rates from Fully and
Partially Observed Data: Uncertainty Propagation, Evidence Synthesis, and Model Calibration. Medical
Decision Making 2005; 25(6): 633-645.
Baio G. Bayesian Methods in Health Economics. Chapman & Hall/CRC Biostatistics Series, 2013.
Grover G, Gadpayle AK, Swain PK et al. A Multistate Markov Model Based on CD4 Cell Count for HIV/AIDS
Patients on Antiretroviral Therapy (ART). International Journal of Statistics in Medical Research 2013; 2: 144-
Shoko C, Chikobvu D. Time-homogeneous Markov process for HIV/AIDS progression under a combination
treatment therapy: cohort study, South Africa. Theor Biol Med Model 2018; 15: 3.
Kind P, Brooks R, Rabin R. EQ-5D Concepts and Methods: A Developmental History. Springer, Dordrecht. 2005.13. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36.
Journal of Health Economics 2002; 21(2): 271-292.
Tseng YK, Hsieh F, Wang JL. Joint modelling of accelerated failure time and longitudinal data. Biometrika 2005;
(3): 587-603.
Tsiatis AA, Davidian M. Joint modeling of longitudinal and time-to-event data: an overview. Statistica Sinica
; 14: 809-834.
Yu M, Law NJ, Taylor JMG et al. Joint Longitudinal-Survival-Cure Models and Their Application to Prostate
Cancer. Statistica Sinica 2004; 14: 835-862.
Rizopoulos D. JM: An R package for the joint modelling of longitudinal and time-to-event data. Journal of
Statistical Software 2010; 35(9).
Jackson C, Stevens J, Ren S et al. Extrapolating survival from randomized trials using external data: a review of
methods. Medical Decision Making 2017; 37: 377-390.
May MT, Gompels M, Delpech V et al. Impact on life expectancy of HIV-1 positive individuals of CD4R cell
count and viral load response to antiretroviral therapy. AIDS 2014; 28(8): 1193-1202.
Egger M, Johnson LF. Estimating trends in life expectancy in HIV-positive individuals. The Lancet Global Health 2015; 3: e122-23.
Katz IT, Maughan-Brown B. Improved life expectancy of people living with HIV: who is left behind? The Lancet
HIV 2017; 4: e324-6.
Teeraananchai S, Kerr SJ, Amin J et al. Life expectancy of HIV-positive people after starting combination
antiretroviral therapy: a meta-analysis. HIV Medicine, 2016.
Rungta A, Hooja S, Vyas N et al. Enumeration of CD4 and CD8 T lymphocytes in healthy HIV seronegative adults of northwest India: A preliminary study. Indian Journal of Pathology and Microbiology 2008; 51(1): 127-129.
Shahapur PR, Bairy I, Shivananda PG. CD4 and CD8 reference counts in normal healthy south indian adults.
Indian Journal of Medical Microbiology 2008; 26(3): 280-290.
Ramalingam S, Kannangai R, Zachariah A et al. CD4 counts of normal and HIV-infected south Indian
adults:Do we need a new staging system? The National Medical Journal of India 2001; 14: 335-339.
Uppal SS, Verma S, Dhot PS. Normal Values of CD4 and CD8 lymphocyte subsets in healthy indian adults
and the effects of sex, age, ethnicity, and smoking. Cytometry Part B: Clinical Cytometry 2003; 52B: 32-36.
Bender MA, Kumarasamy N, Mayer KH et al Costeffectiveness of tenofovir as first-line antiretroviral
therapy in India. Clinical Infectious Diseases 2010; 50: 416-425.
Copyright (c) 2019 Journal of Communicable Diseases (E-ISSN: 2581-351X & P-ISSN: 0019-5138)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
